Citation
Kim, Hyo Song, et al. "Fibroblast Growth Factor Receptor 1 Gene Amplification Is Associated With Poor Survival in Patients With Resected Esophageal Squamous Cell Carcinoma." Oncotarget, vol. 6, no. 4, 2015, pp. 2562-72.
Kim HS, Lee SE, Bae YS, et al. Fibroblast growth factor receptor 1 gene amplification is associated with poor survival in patients with resected esophageal squamous cell carcinoma. Oncotarget. 2015;6(4):2562-72.
Kim, H. S., Lee, S. E., Bae, Y. S., Kim, D. J., Lee, C. G., Hur, J., Chung, H., Park, J. C., Jung, D. H., Shin, S. K., Lee, S. K., Lee, Y. C., Kim, H. R., Moon, Y. W., Kim, J. H., Shim, Y. M., Jewell, S. S., Kim, H., Choi, Y. L., & Cho, B. C. (2015). Fibroblast growth factor receptor 1 gene amplification is associated with poor survival in patients with resected esophageal squamous cell carcinoma. Oncotarget, 6(4), 2562-72.
Kim HS, et al. Fibroblast Growth Factor Receptor 1 Gene Amplification Is Associated With Poor Survival in Patients With Resected Esophageal Squamous Cell Carcinoma. Oncotarget. 2015 Feb 10;6(4):2562-72. PubMed PMID: 25537505.
TY - JOUR
T1 - Fibroblast growth factor receptor 1 gene amplification is associated with poor survival in patients with resected esophageal squamous cell carcinoma.
AU - Kim,Hyo Song,
AU - Lee,Seung Eun,
AU - Bae,Yoon Sung,
AU - Kim,Dae Joon,
AU - Lee,Chang-Geol,
AU - Hur,Jin,
AU - Chung,Hyunsoo,
AU - Park,Jun Chul,
AU - Jung,Da Hyun,
AU - Shin,Sung Kwan,
AU - Lee,Sang Kil,
AU - Lee,Yong Chan,
AU - Kim,Hye Ryun,
AU - Moon,Yong Wha,
AU - Kim,Joo Hang,
AU - Shim,Young Mog,
AU - Jewell,Susan S,
AU - Kim,Hyunki,
AU - Choi,Yoon-La,
AU - Cho,Byoung Chul,
PY - 2015/09/11/received
PY - 2015/12/09/accepted
PY - 2014/12/25/entrez
PY - 2014/12/30/pubmed
PY - 2016/1/16/medline
SP - 2562
EP - 72
JF - Oncotarget
JO - Oncotarget
VL - 6
IS - 4
N2 - To investigate the frequency and the prognostic impact of fibroblast growth factor receptor 1 (FGFR1) gene amplification in 526 curatively resected esophageal squamous cell carcinoma (ESCC). Using fluorescent in situ hybridization, high amplification was defined by an FGFR1/centromer 8 ratio is ≥ 2.0, or average number of FGFR1 signals/tumor cell nucleus ≥ 6.0, or percentage of tumor cells containing ≥ 15 FGFR1 signals or large cluster in ≥ 10%. Low amplification was defined by ≥ 5 FGFR1 signals in ≥ 50%. FGFR2 and FGFR3 mutations were assessed by direct sequencing in 388 cases and no mutation was detected. High and low amplification were detected in 8.6% and 1.1%, respectively. High FGFR1 amplification had significantly shorter disease-free survival (34.0 vs 158.5 months P=0.019) and overall survival (52.2 vs not reached P=0.022) than low/no amplification group. After adjusting for sex, smoking, stage, histology, and adjuvant treatment, high FGFR1 amplification had a greater risk of recurrence (adjusted hazard ratio [AHR], 1.6; P=0.029) and death (AHR, 1.53; P=0.050). High amplification was significantly higher in current smokers than former and never-smokers (Ptrend<0.001) and increased proportional to smoking dosage. High FGFR1 amplification is a frequent oncogenic alteration and an independent poor prognostic factor in resected ESCC.
SN - 1949-2553
UR - https://www.unboundmedicine.com/medline/citation/25537505/Fibroblast_growth_factor_receptor_1_gene_amplification_is_associated_with_poor_survival_in_patients_with_resected_esophageal_squamous_cell_carcinoma_
L2 - https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.2944
DB - PRIME
DP - Unbound Medicine
ER -